Scleroderma Research Foundation

The Scleroderma Research Foundation Appoints Dr. Gregory Gordon as Chief Medical Officer

Retrieved on: 
Thursday, January 25, 2024
Columbia Law School, Patient, JD, Therapy, State university system, Research, PTC Therapeutics, SAN, Scleroderma, Boehringer, Autoimmune disease, CONQUEST, Scleroderma Research Foundation, CMO, TiGenix, Harvard Vanguard Medical Associates, Doctor of Philosophy, SRF, Drug, Physician

SAN FRANCISCO, Jan. 25, 2024 /PRNewswire/ -- The Scleroderma Research Foundation (SRF)— the nation's largest non-profit funder of scleroderma research—announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer (CMO). As CMO, Dr. Gordon will provide both strategic management and operations oversight for the recently announced global clinical trial program CONQUEST, which will involve 130 medical centers in 22 countries. He will also liaise with CONQUEST's two pharmaceutical partners—Sanofi and Boehringer Ingelheim—as well as any other partners that opt to bring innovative therapies to the CONQUEST platform. Dr. Gordon's contributions are expected to add focus to the ongoing work of SRF—in particular regarding its efforts to bring new and innovative therapeutic alternatives to scleroderma patients and the scleroderma community worldwide.

Key Points: 
  • SAN FRANCISCO, Jan. 25, 2024 /PRNewswire/ -- The Scleroderma Research Foundation (SRF)— the nation's largest non-profit funder of scleroderma research—announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer (CMO).
  • "Dr. Gordon, with his impressive track record spanning over fifteen years in pivotal leadership roles in the biotechnology industry, brings a unique and vital perspective to the Scleroderma Research Foundation.
  • "With CONQUEST, the Scleroderma Research Foundation is deepening its commitment and support for research that addresses the high unmet needs of scleroderma patients.
  • Before attending medical school at the State University of New York at Stony Brook, Dr. Gordon earned a J.D.

Cool Comedy • Hot Cuisine, A Tribute to Bob Saget, Raises More Than $1.2M for Scleroderma Research Foundation as Part of the 19th Annual New York Comedy Festival

Retrieved on: 
Friday, November 10, 2023
Carolines, Research, SAN, Scleroderma Research Foundation, Scleroderma, Disease, Patient, Human, Heart, Music, A Long December, CBS, New York Comedy Festival, MD, Crow, Laughter, Skin, Name, SRF, Fibrosis, Entertainment, Film industry, Saget

SAN FRANCISCO, Nov. 10, 2023 /PRNewswire/ -- Last night, the Scleroderma Research Foundation (SRF) presented its annual Cool Comedy • Hot Cuisine, a tribute to Bob Saget, raising more than $1.2M for the SRF as part of the 19th Annual New York Comedy Festival.

Key Points: 
  • SAN FRANCISCO, Nov. 10, 2023 /PRNewswire/ -- Last night, the Scleroderma Research Foundation (SRF) presented its annual Cool Comedy • Hot Cuisine, a tribute to Bob Saget, raising more than $1.2M for the SRF as part of the 19th Annual New York Comedy Festival.
  • Hirsch was a dear friend of Bob Saget and had a long and generous history of helping him to raise funds and awareness for scleroderma research.
  • I'm very grateful to her and she does a lot of work for the Scleroderma Research Foundation," adds Jeff Ross.
  • The SRF funds and facilitates the most promising, highest-quality research aimed at improved therapies and, ultimately, a cure for scleroderma.

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma

Retrieved on: 
Wednesday, October 11, 2023
Investigational New Drug, Engineering, Food, Scleroderma, Trial of the century, IND, Scleroderma Research Foundation, FDA, Therapy, CAR, Immune system, CD19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Optimism, Patient, Pharmaceutical industry, Vaccine

EMERYVILLE, Calif., Oct. 11, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the clearance of the third Investigational New Drug (IND) application for KYV-101 by the U.S. Food and Drug Administration (FDA). This will allow Kyverna to initiate a Phase 1/2 open-label, multicenter study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).

Key Points: 
  • This will allow Kyverna to initiate a Phase 1/2 open-label, multicenter study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
  • "We welcome Kyverna's enthusiasm and interest to push forward with their CAR T approach in scleroderma patients with the KYSA-5 trial," said Luke Evnin, chairman of the Scleroderma Research Foundation.
  • "We are immensely proud of being able to bring KYV-101 to patients suffering from scleroderma," said Peter Maag, Ph.D., chief executive officer of Kyverna Therapeutics.
  • "We are keen to initiate our KYSA-5 trial in this new patient population and generate data to support our KYV-101 design goals.

The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform

Retrieved on: 
Tuesday, October 3, 2023
Pulmonary fibrosis, Sanofi, Boehringer Ingelheim, Clinical trial, Scleroderma Research Foundation, ILD, SRF, Research, Patient, SAN, CONQUEST, Scleroderma, Fine chemical

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- The Scleroderma Research Foundation (SRF), the nation's largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.

Key Points: 
  • SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- The Scleroderma Research Foundation (SRF), the nation's largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • Boehringer Ingelheim is the second company to join CONQUEST; the platform's inaugural partner, Sanofi, was announced in August of this year.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, "Boehringer Ingelheim has a rich history of innovation in the Interstitial Lung Disease (ILD) arena and is bringing their considerable experience and expertise to CONQUEST.
  • We have chosen to partner with the SRF in scleroderma because we believe the benefits of highly innovative CONQUEST platform for all of the CONQUEST stakeholders – patients, clinical trial sites, and innovators – are dramatic and important."

Cool Comedy • Hot Cuisine: A Tribute to Bob Saget Benefitting the Scleroderma Research Foundation Wednesday, November 8 at the Edison Ballroom, New York City as Part of the 19th Annual New York Comedy Festival

Retrieved on: 
Monday, October 2, 2023
Heart, Music, Scleroderma Research Foundation, Friends, New York Comedy Festival, Research, SRF, Carolines, SAN, Edison Theatre, Crow, Laughter, Disease, Film industry, Compact Disc manufacturing, Scleroderma

Hosted by Jeff Ross, Cool Comedy • Hot Cuisine is co-chaired by Susan Feniger, Regina Hall, and Kelly Rizzo.

Key Points: 
  • Hosted by Jeff Ross, Cool Comedy • Hot Cuisine is co-chaired by Susan Feniger, Regina Hall, and Kelly Rizzo.
  • The inaugural award will be presented to Caroline Hirsch, founder and owner of Carolines and the New York Comedy Festival.
  • "I am truly humbled to be receiving the inaugural Bob Saget Legacy Award from the Scleroderma Research Foundation.
  • "Laughter was at the heart of everything Bob did, and Cool Comedy Hot Cuisine is no exception.

Learn the Facts About Interstitial Lung Disease on ILD Day, Sept. 13

Retrieved on: 
Thursday, August 31, 2023
Sarcoidosis, University of California, San Diego Performance-Based Skills Assessment, Pulmonary fibrosis, Polymyositis, University, DM, Advocacy, Oxygen, Cough, Scar, ILD, Scleroderma, Dermatomyositis, Inflammation, American Thoracic Society, Government, Rheumatoid arthritis, Myositis, Organization, Patient, Stanford University School of Medicine, Scleroderma Research Foundation, CDT, Research, IPF, Respiratory disease, Idiopathic pulmonary fibrosis, Education, Fatigue, Disease, Medical imaging, Nursing

CHICAGO, Aug. 31, 2023 /PRNewswire/ -- With more than 250,000 Americans living with interstitial lung disease (ILD) and pulmonary fibrosis (PF), nine organizations are joining forces to present the third annual ILD Day on Wednesday, Sept. 13, to drive awareness of the diseases.

Key Points: 
  • CHICAGO, Aug. 31, 2023 /PRNewswire/ -- With more than 250,000 Americans living with interstitial lung disease (ILD) and pulmonary fibrosis (PF), nine organizations are joining forces to present the third annual ILD Day on Wednesday, Sept. 13, to drive awareness of the diseases.
  • Pulmonary fibrosis can be seen in many types of ILD and the damage caused by ILD can be irreversible and worsen over time.
  • "Since the symptoms of ILD are similar to other more common illnesses, it can be difficult to diagnose.
  • To register for the ILD Day webinar or for more information about ILD, visit ILDDay.org .

The Scleroderma Research Foundation (SRF) Launches Conquest Trial Platform to Address Critical Issues in Clinical Development and Enable Advances in Scleroderma Therapeutics

Retrieved on: 
Tuesday, August 1, 2023
General Health, Foundation, Health, Philanthropy, Scleroderma Research Foundation, Drug development, University, Therapy, Atmosphere, Clinical trial, Cancer, British Lung Foundation, ILD, Keck School of Medicine of USC, Research, FVC, CONQUEST, Autoimmunity, Fibrosis, Vital capacity, SRF, Imperial College London, MD, Patient, Autoimmune disease, Vascular disease, Rheumatology, Disease, Frederick, Knowledge, Ecosystem, Respiratory Medicine, British, Pharmaceutical industry, Vaccine, Medicine, Scleroderma, Sanofi

This groundbreaking effort, conceived and led by the SRF, will enroll patients across more than 130 centers in more than 22 countries. CONQUEST offers advantages to all stakeholders -- patients, physician, and drug innovators -- and provides for a seamless transition to a global Phase 3 trial, investigation of a drug’s activity in a wide range of genetic backgrounds, as well as rapid patient enrollment. By assembling a global network of high-performing centers that are dedicated to treating scleroderma, the SRF and its pharmaceutical partners expect to make enduring contributions to the scleroderma community by creating an ecosystem designed to enable success in new drug development.

Key Points: 
  • The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Sanofi will contribute the first experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF.
  • In the future, the CONQUEST platform will be expanded to address other manifestations of scleroderma.
  • Luke Evnin, Ph.D., Chairman of the Scleroderma Research Foundation, commented, “Our commitment to innovation in scleroderma spans basic, translational, and clinical research.
  • The initial run of CONQUEST is expected to enroll approximately 400 patients and trial initiation is targeted for Q4 2023.

The Scleroderma Research Foundation Will Be Featured on "Behind The Mystery" Presented by The Balancing Act® Airing on Lifetime®

Retrieved on: 
Thursday, February 16, 2023
Human, Stanford University School of Medicine, Rheumatology, Rare Disease Day, Scleroderma Research Foundation, Scleroderma, Division, Melissa, Patient, SRF, Fibrosis, Skin, Research, Rare disease, Family, Mystery, Immunology, Balancing, Heart, Disease, SAN, Medical device, Pharmaceutical industry, Dermatology, Medicine

SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- The Scleroderma Research Foundation (SRF) will shine a light on scleroderma—a rare, often misdiagnosed disease—on "Behind The Mystery," a specialized series presented by The Balancing Act® and airing on Lifetime® on February 20 and on Rare Disease Day, February 28. Scleroderma Research Foundation Founding Board Member Susan Feniger, Dr. Lorinda Chung, Professor of Medicine and Dermatology, Division of Immunology and Rheumatology at Stanford University School of Medicine, and scleroderma patient Melissa will share insights about the disease and research developments supported by the Scleroderma Research Foundation—the country's first and leading nonprofit investor in medical research into scleroderma.

Key Points: 
  • Scleroderma Research Foundation Founding Board Member Susan Feniger, Dr. Lorinda Chung, Professor of Medicine and Dermatology, Division of Immunology and Rheumatology at Stanford University School of Medicine, and scleroderma patient Melissa will share insights about the disease and research developments supported by the Scleroderma Research Foundation—the country's first and leading nonprofit investor in medical research into scleroderma.
  • "The Scleroderma Research Foundation is laser-focused on funding and facilitating research in order to advance treatments and find a cure for scleroderma so that people don't need to suffer," says Joanne Gold, Executive Director of the Scleroderma Research Foundation.
  • "The Scleroderma Research Foundation works with top leaders across a variety of fields in order to expand our knowledge of the causes of scleroderma and improve treatments for patients.
  • The Scleroderma Research Foundation funds and facilitates the most promising, highest quality research aimed at improved therapies and, ultimately, a cure for scleroderma.

Cool Comedy • Hot Cuisine: A Tribute to Bob Saget Raises More Than $1.2M for Scleroderma Research Foundation

Retrieved on: 
Friday, September 23, 2022
Beverly Wilshire Hotel, University, Time, Regina Hall, Twitter, Disease, Name, Scleroderma, View, Johns Hopkins School of Medicine, Mandel, Social media, SRF, Instagram, Scleroderma Research Foundation, Science, Stanford University, Music, Heart, Research, SAN, Awareness, Multimedia, University of California, Entertainment, Public relations, Facebook

Some of the world's most talented performers generously donated their time to take to the stage to raise funds for the Scleroderma Research Foundation and to find a cure.

Key Points: 
  • Some of the world's most talented performers generously donated their time to take to the stage to raise funds for the Scleroderma Research Foundation and to find a cure.
  • Cool Comedy Hot Cuisine featured performances byHowie Mandel and Kevin Nealon, with Joel McHale leading the live auction.
  • As a longtime supporter and board member of Scleroderma Research Foundationthe country's first and leading nonprofit investor in medical research into sclerodermaBob Saget spearheaded Cool Comedy Hot Cuisine for 30 years.
  • The Scleroderma Research Foundation is focused on bringing the best minds in science together to find a cure for scleroderma.

Second Annual ILD Day to Drive Awareness of Interstitial Lung Disease on Sept. 14

Retrieved on: 
Wednesday, August 24, 2022
Inflammation, CDT, BBB, Scar, Fatigue, Rheumatoid arthritis, Research, Caregiver, CEO, Pulmonary fibrosis, Awareness, Disease, Scleroderma Research Foundation, PFF, Sarcoidosis, Scleroderma, Interstitial lung disease, Organization, Foundation, National Health Council, DM, PF, Patient, Better Business Bureau, Myositis, Certification, Dermatomyositis, IPF, Oxygen, Cystic Fibrosis Foundation, Cough, Polymyositis, Charity Navigator, Idiopathic pulmonary fibrosis, Medical device, Medicine, ILD

CHICAGO, Aug. 24, 2022 /PRNewswire/ -- Nine organizations are joining forces to present the second annual ILD Day on Wednesday, Sept. 14, to drive awareness of interstitial lung disease (ILD).

Key Points: 
  • CHICAGO, Aug. 24, 2022 /PRNewswire/ -- Nine organizations are joining forces to present the second annual ILD Day on Wednesday, Sept. 14, to drive awareness of interstitial lung disease (ILD).
  • PF can be seen in many types of ILD and the damage caused by ILD can be irreversible and worsen over time.
  • "The goal of ILD Day is to expand the understanding of ILD among patients and healthcare providers, and to share resources and support for those who are living with the disease."
  • ILD Day was created to drive awareness of interstitial lung disease (ILD) in 2021 and is recognized annually on the second Wednesday in September.